New hope for aggressive lung cancer: drug cocktail plus Low-Dose radiation shows promise
NCT ID NCT06477523
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new combination treatment for people with extensive-stage small cell lung cancer who have not had prior therapy. It combines an experimental immunotherapy (AK104) with standard chemotherapy and low-dose radiation to see if it can better control the cancer. The trial involves 57 adults aged 18-80 and focuses on safety and how long the cancer stays under control.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCLC, EXTENSIVE STAGE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
China West Hospital
Chengdu, Sichuan, 610000, China
-
West China Hospital, Sichuan University
Chengdu, Sichuan, 610041, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted drug combo outperform standard chemo for tough lung cancer?
- New drug cocktail aims to shrink tough lung cancers
- New drug cocktail aims at resistant lung cancer
- New drug combo aims to outperform standard care in aggressive lung cancer
- New combo therapy targets tough lung cancer in early trial
- New PET scan probe could sharpen lung cancer detection